Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Takeda Pharmaceutical Co's 5-Year Yield-on-Cost % or its related term are showing as below:
During the past 13 years, Takeda Pharmaceutical Co's highest Yield on Cost was 6.95. The lowest was 3.05. And the median was 4.94.
LTS:0RN3's 5-Year Yield-on-Cost % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.28 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Takeda Pharmaceutical Co (LTS:0RN3) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Takeda Pharmaceutical Co 5-Year Yield-on-Cost % Related Terms
LTS:0RN3 vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Takeda Pharmaceutical Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Takeda Pharmaceutical Co 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Takeda Pharmaceutical Co's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Takeda Pharmaceutical Co's 5-Year Yield-on-Cost % falls into.
Takeda Pharmaceutical Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Takeda Pharmaceutical Co (LTS:0RN3) has a 5-Year Yield-on-Cost % of 0.00 as of Aug. 13, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Takeda Pharmaceutical Co and its competitors. Over the past decade, Takeda Pharmaceutical Co's 5-Year Yield-on-Cost % has ranged from 3.05 to 6.95. According to the industry distribution chart, Takeda Pharmaceutical Co ranks #170 out of 511 companies in the Drug Manufacturers industry, placing it in the top 33.3%.
Is Takeda Pharmaceutical Co's 5-Year Yield-on-Cost % too high?
Takeda Pharmaceutical Co's current 5-Year Yield-on-Cost % is 0.00. Over the past 10 years, this metric has ranged from a low of 3.05 to a high of 6.95. Based on the distribution chart, Takeda Pharmaceutical Co ranks #170 out of 511 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Takeda Pharmaceutical Co has a GF Score™ of 65/100, reflecting its overall financial health beyond just this single metric.
How does Takeda Pharmaceutical Co's 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Takeda Pharmaceutical Co ranks #170 out of 511 companies for 5-Year Yield-on-Cost %. This puts Takeda Pharmaceutical Co in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.28. Historically, Takeda Pharmaceutical Co's own 5-Year Yield-on-Cost % has ranged from 3.05 to 6.95 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.28, based on 511 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Takeda Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Takeda Pharmaceutical Co's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Takeda Pharmaceutical Co stock overvalued right now?
Takeda Pharmaceutical Co (LTS:0RN3) has a current 5-Year Yield-on-Cost % of 0.00. The stock's GF Value™ is €30.76, compared to a current price of €37.59 — trading 22.2% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Takeda Pharmaceutical Co's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Takeda Pharmaceutical Co (LTS:0RN3), the current 5-Year Yield-on-Cost % is 0.00 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Takeda Pharmaceutical Co (LTS:0RN3) Overvalued in 2026?
Based on GuruFocus' analysis, Takeda Pharmaceutical Co stock appears to be overvalued.
The current stock price of €37.59 is trading 22.2% above its estimated GF Value™ of €30.76.
Key valuation signals for LTS:0RN3:
5-Year Yield-on-Cost %: 0.00
GF Value™: €30.76 vs. price of €37.59 (22.2% above fair value)
No single metric tells the full story. See the LTS:0RN3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
65GF Score
Get the complete analysis for LTS:0RN3
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RN3 has been successfully added to your 
